tbuckley/cabot-search huggingface dataset:
TMOD-17. CONVERGENCE OF BMI1 AND CHD7 ON ERK SIGNALLING IN MEDULLOBLASTOMA
Authors: Silvia Marino, Adrian Dubuc, Mariane Da Cunha Jaeger, Sorana Morrissy, Michael Taylor, Xinyu Zhang
Journal: Neuro-Oncology (2016)

Medulloblastoma is the most common malignant brain tumour of childhood, and a common cause of pediatric morbidity and mortality. Medulloblastomas have been dissected into four distinct molecular subgroups (WNT, SHH, Group 3, Group 4) with divergent clinical and biological profiles. The Polycomb group protein Bmi1 is upregulated in a variety of cancers, has a positive correlation with clinical grade/stage and poor prognosis and it is a highly druggable molecule. Bmi1 is overexpressed across all MB subgroups; the growth of SHH and Group 4 MB is dependent on Bmi1 expression. Genome wide in vivo insertional mutagenesis (T2Onc2) driven by the Sleeping Beauty (SB11) transposase in glutamatergic progenitor cells engineered to over-express Bmi1 results in medulloblastoma formation, while neither Bmi1 over-expression nor T2Onc2 transposition alone drives tumorigenesis. On the Bmi1 over-expressing background, we observe frequent T2Onc2 inactivating insertions in the chromatin remodelling factor Chd7 (Chromodomain helicase DNA binding factor 7), suggesting that Bmi1 overexpression and Chd7 loss of function cooperate to induce medulloblastoma. High expression of BMI1 in combination with low expression of CHD7 is associated with a poor prognosis in human medulloblastoma. Loss of function mutations of CHD7are observed in medulloblastoma, particularly in Group 4. CHD7 knockdown in patient-derived Group 4 medulloblastoma cells led to increased proliferation and increased expression of markers of undifferentiated and highly proliferative progenitor cells both in vitro and in xenografts. Importantly, we show the BMI1-dependency of the phenotype observed upon CHD7 knockdown and the molecular convergence on ERK signalling. These finding extend the current knowledge of the role of BMI1 and CHD7 in medulloblastoma pathogenesis and raise the possibility that pharmacological targeting of BMI1 or ERK may be particularly indicated in a subgroup of medulloblastoma with low expression level of CHD7.
Dying at Home
Authors: Wallace I. Sampson
Journal: JAMA (1976)

<h3>To the Editor.—</h3> A recent communication to the QUESTIONS AND ANSWERS section of theJournal(234:1068, 1975) questioned how physicians handle patients who wish to die at home. Two well thought-out and explicit answers were given by Drs Krant and Kennedy, whose contributions to oncology and whose eminence in the field are well-recognized. However, it seemed to me that one could look at the situation from a different angle. As a hematologist-oncologist, I, too, have been faced with the question, but it has not been asked as frequently as it should be. I ask a different question: "Why is it that so many patients, families of patients, and physicians expect that the dying happens in a hospital?" The answer could be simple: it has become a social and psychological pattern in modern society to recognize the hospital as a place for emotional support and the place where people can die,
Efficacy of platinum-based chemotherapy after cranial irradiation in patients with brain metastasis from non-small cell lung cancer
Authors: D. Y. Kim, K. W. Lee, T. Yun, J. H. Kim, D. W. Kim, S. A. Im, T. Y. Kim, D. S. Heo, Y. J. Bang, N. K. Kim
Journal: Journal of Clinical Oncology (2004)

1575 Background: Although chemotherapy has not yet emerged as a standard therapy for patients with brain metastasis, evidences suggest that chemotherapy may have a role in the treatment of selected patients. Methods: We have evaluated 63 consecutive non-small cell lung cancer (NSCLC) patients with synchronous brain metastasis (BM) who had not been previously treated. After cranial radiation therapy (RT), all patients in 'the chemotherapy arm' (CTX) were treated with platinum-based combination chemotherapy, and best supportive care was selected for patients in 'the no-chemotherapy arm' (no-CTX). Results: The median age of all patients was 55 years. The performance status of all patients was ECOG grade 1–2. Thirty-one of the 63 patients received systemic chemotherapy. In the CTX arm, a paclitaxel + platinum (cisplatin or carboplatin) chemotherapy was administered in 38.7%, gemcitabine + platinum in 25.8%, and vinorelbine + platinum in 25.8% as the first-line chemotherapy. Seventeen patients were treated with a second-line chemotherapy, and 8 patients of them received paclitaxel + platinum followed by gemcitabine + platinum or vice versa. Extracranial overall responses were 36% in the first-line chemotherapy and 35% in the second-line, and the median response durations were 29.1 weeks and 30.4 weeks, respectively. The pattern of treatment failure revealed that 'progression of the extracranial lesion' (58.1%) was occurred more frequently than the 'aggravation of neurologic status' (19.4%) in the first-line chemotherapy. The causes of failure were identical in the second-line chemotherapy. The median overall survival of the CTX arm is significantly longer than that of the no-CTX arm (58.1 weeks vs. 19.0 weeks, p<0.001). Toxicity in the CTX arm was tolerable. Conclusions: The systemic chemotherapy was effective in increasing the overall survival of patients with BM from NSCLC, and extracranial progression was the main cause of chemotherapeutic failure. No significant financial relationships to disclose.
Inhibition of connexin hemichannels alleviates non-alcoholic steatohepatitis in mouse
Authors: J. Willebrords, I.V.A. Pereira, T.C. da Silva, V.M. Govoni, M. Maes, S.C. Yanguas, R.M. Rodrigues, E. Decrock, L. Leybaert, I. Leclercq, B. Cogliati, M. Vinken
Journal: Journal of Hepatology (2017)
NCCN News2016 NCCN Nursing Program Addresses Information Needs for Oncology Nurses2016 NCCN Fellows Recognition Program Explores New Horizons in Quality Cancer CareFor Breast Cancer, When to Screen or Not to Screen? That is the Question Plaguing the Minds of US Women—and Their CliniciansIn the Face of Chronic Pain, Clinicians Seek Best Practices for Management while Evading Opioid Abuse
Journal: Journal of the National Comprehensive Cancer Network (2016)
INTERNATIONAL ABSTRACTS
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Rational Clinical Examination
Authors: Michael G. Lamb
Journal: JAMA (1992)

<h3>To the Editor.</h3> —The article by Drs Williams and Simel<sup>1</sup>is a laudable contribution to the study of bedside diagnosis to which<i>JAMA</i>has wisely made a commitment. I would like to add some additional comments concerning the diagnosis of ascites by physical examination. In my experience, the combination of abdominal distention, bulging flanks, and an everted umbilicus is almost always due to ascites. Rarely, false positives such as a large ovarian cyst will produce this sign. Unfortunately, the sign of the everted umbilicus has not been subjected to rigorous study. A valuable technique taught by Jack Myers, MD, (famed clinician and professor emeritus at the University of Pittsburgh [Pa]) consists of placing the examiner's hands, volar side up, under both bulging flanks of the supine patient, followed by flicking the flanks upward a few inches. If ascites is present, a fluid wave will be felt falling into the
Polymicrobial Bacteremia
Authors: PAUL E. HERMANS
Journal: Annals of Internal Medicine (1970)

Polymicrobial bacteremia, defined as a bacteremic episode due to at least two different organisms isolated from the same blood sample, occurred in 46 patients (6% of all patients with bacteriologically established bacteremia) in an 18-month period. The mortality was 37%. Patients with gastrointestinal, biliary, or hepatic abnormalities represented the single largest group (30%); in this group and in patients with urinary tract abnormalities pathologic processes causing obstruction were common. A relatively benign clostridial bacteremia without underlying gas gangrene was found in four patients and should be differentiated from the clostridial bacteremia with hemolysis which may be seen as a terminal event in patients with gas gangrene. The rare entity of polymicrobial endocarditis or endarteritis can easily be overlooked; it was seen in three patients.
Report: Exposure to Alcoholism in Family
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dance Me Loose
Authors: Zenonas Danilevicius
Journal: JAMA (1978)

Do you remember that old song "Dance Me Loose?" The girl in the song complained about being held too tight. Well, this is not the only danger involved in dancing, especially stage dancing. Washington<sup>1</sup>reminds us that when "we are seated in a large theater about to witness a performance by one of America's fine dance companies," and "the house lights dim and the melancholy strains of the overture from Tchaikovsky's<i>Swan Lake</i>fill the great hall," the dancers are often exposed to a whole gamut of orthopedic injuries. The fine structure and functional ability of the human body, which allow such beautiful and seemingly effortless movement as in ballet, are to be admired. But what sort of orthopedic problems do these dancers encounter in their work? Is the pattern of injuries of the various areas of the body in dancers the same as in athletes? How are these problems
The two-edged sword
Authors: W. B. Smith
Journal: JAMA (1979)

A unanimous opinion of the Supreme Court is an unusual phenomenon today, when it seems that almost every other decision of that august court is determined by a single vote. Furthermore, it is encouraging to read the opinion written by Chief Justice Warren Burger in the case of<i>Addington vs Texas</i>. The reader must appreciate the wisdom and sensitivity disclosed by the careful analysis in that opinion, which deals with the legal problems inherent in the civil commitment of the mentally ill. The Court's determination of the standard of proof required by the due process clause of the Fourteenth Amendment for an involuntary commitment to a state mental hospital is wrapped in a comprehensive delineation of rights and duties. The main argument centered on use of the same standard of proof required in criminal actions, ie, proof beyond a reasonable doubt, as opposed to the more moderate standard of clear
Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline <i>BRCA1</i> and <i>BRCA2</i> mutations (gBRCAm).
Authors: Talia Golan, Hedy L. Kindler, Philipp Schatz, Teodora Goranova, Gershon Y. Locker, Karen Cui, Katia Schlienger, David McGuinness, J. Andrew Williams, Maria Orr, Thorsten Gutjahr, Yu-Zhen Liu
Journal: Journal of Clinical Oncology (2020)

4621 Background: The POLO study (NCT02184195) showed that mPaC patients (pts) with a deleterious or suspected deleterious gBRCAm, and whose disease had not progressed during ≥16 weeks of first-line platinum-based chemotherapy, had significantly longer progression-free survival (PFS, primary endpoint) with maintenance olaparib vs placebo: median 7.4 vs 3.8 months, hazard ratio (HR) 0.53; P=0.004. PFS benefit was observed in pts with g BRCA1m (HR 0.40) and g BRCA2m (HR 0.63). The POLO study represents the largest BRCAm prevalence study in pancreatic cancer. We report additional exploratory analysis to further characterize patient gBRCAm profiles, including the relationship with efficacy. Methods: Pts were enrolled based on either a previously identified gBRCAm status from a local test result and subsequently confirmed by central testing, or a prospectively identified gBRCAm. Pts received maintenance olaparib 300 mg twice daily (tablet) or placebo. PFS was assessed by blinded independent central review (modified RECIST v1.1). Results: Of 3194 prospectively screened pts, a valid BRCA test result was obtained for 3175 (99%) from 12 countries; gBRCAm prevalence was 6.2% in pts not previously known to harbor a gBRCAm (196/3175; 1.6% g BRCA1m, 4.5% g BRCA2m). In countries (n=8) with &gt;100 pts prospectively tested, highest gBRCAm prevalence was 9.2% (USA) and lowest 4.0% (Spain). Prevalence by race (&gt;100 pts); 6.4% Caucasian, 4.6% Asian. In total, 154 pts with a gBRCAm satisfied all eligibility criteria and were randomized (106 prospectively tested and 48 by local test [44/48 subsequently confirmed by Myriad testing]). 37/154 (24%) randomized pts carried a common Ashkenazi Jewish founder mutation, the majority being from Israel (21 pts). From a total of 151 variants, frameshift mutations were most frequent (g BRCA1m 69.6%, g BRCA2m 71.4%) followed by nonsense mutations (g BRCA1m 6.5%, g BRCA2m 17.1%). The efficacy (PFS) of olaparib vs placebo in the different subgroups are shown in the table. Conclusions: In pts with mPaC enrolled in POLO, g BRCA2m were more prevalent than g BRCA1m and mutation type was predominantly frameshift. PFS benefit was consistent across a heterogenous spectrum of gBRCAm and with the previously reported full analysis set. Clinical trial information: NCT02184195 . [Table: see text]
Data Errors
Authors: Signe Møller-Bisgaard, Mikkel Østergaard
Journal: JAMA (2019)

Sarah Alexander, MD; Brian T. Fisher, DO, MSCE; Aditya H. Gaur, MD; Christopher C. Dvorak, MD; Doojduen Villa Luna, MS; Ha Dang, PhD; Lu Chen, PhD; Michael Green, MD, MPH; Michael L. Nieder, MD; Beth Fisher, MSN; L. Charles Bailey, MD, PhD; John Wiernikowski, Pharm D; Lillian Sung, MD, PhD; for the Children’s Oncology Group
THE ETIOLOGY OF DENGUE FEVER
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
COPPER IN THE DAILY DIET
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antiarrhythmic Therapy for Prevention of Implantable Cardioverter Defibrillator Shocks—Reply
Authors: Stefan H. Hohnloser, Robin S. Roberts, Eric Fain, Stuart J. Connolly
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SENSATIONALISM AND CRIMINAL SUGGESTION.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Refining the immune class of hepatocellular carcinoma
Authors: Roser Pinyol, Daniela Sia, Miguel Torres-Martin, Huan Wang, Philipp Haber, Marc Puigvehi, Carla Montironi, Miho Maeda, Wei Qiang Leow, Elizabeth Harrod, Patricia Taik, Chinburen Jigjidsuren, Erdenebileg Taivanbaatar, Chinbold Enkhbold, Michael Donovan, Swan Thung, Jaclyn Neely, Vincenzo Mazzaferro, Jeff Anderson, Sasan Roayaie, Myron Schwartz, Augusto Villanueva, Scott Friedman, Andrew Uzilov, Josep Llovet
Journal: Journal of Hepatology (2020)
Symposium of The Southeastern Cancer Research Association
Journal: JNCI Journal of the National Cancer Institute (1974)

Symposium of The Southeastern Cancer Research Association Get access JNCI: Journal of the National Cancer Institute, Volume 52, Issue 6, June 1974, Page 1941, https://doi.org/10.1093/jnci/52.6.1941-a Published: 01 June 1974
Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle.
Authors: G Michel, G Socié, F Gebhard, F Bernaudin, I Thuret, J P Vannier, F Demeocq, G Leverger, J L Pico, H Rubie, F Mechinaud, J Reiffers, N Gratecos, X Troussard, J P Jouet, G Simonin, E Gluckman, D Maraninchi
Journal: Journal of Clinical Oncology (1997)

PURPOSE To evaluate growth, thyroid function, puberty, cardiac function, and the incidence of cataracts in children who received allogeneic bone marrow transplantation (BMT) for acute myeloblastic leukemia (AML) in first complete remission (CR) after a preparation with or without total-body irradiation (TBI). PATIENTS AND METHODS Among 45 children studied, 26 received busulfan-cyclophosphamide (Bu-Cy) in preparation for transplantation and 19 received TBI. TBI was fractionated in nine cases and delivered as a single dose in 10. Four children in the Bu-Cy group and none in the TBI group had received prior cranial radiation. The mean follow-up duration after BMT was 5.9 years for the whole group. RESULTS The mean cumulative changes in height SD score (SDS) were -0.86 at 3 years and -1.56 at 5 years in the TBI group, whereas these changes were only -0.05 and -0.17 in the Bu-Cy group (P &lt; .01 at 3 and 5 years). The 6-year probability of hypothyroidism was 9% +/- 8% in the Bu-Cy group and 43% +/- 15% after TBI (P &lt; .02). Pubertal development after Bu-Cy was assessable in two girls and five boys: both girls had primary ovarian failure, whereas Leydig cell function appeared to be preserved in the five boys. One child who had received anthracycline when he was less than 1 year old developed cardiac dysfunction 4 years after Bu-Cy. The 6-year probability of cataracts was 70% +/- 13% in the TBI group and 0% after Bu-Cy. CONCLUSION The use of Bu-Cy represents an alternative transplant cytoreductive regimen for children with AML in first CR, which can reduce the risk of posttransplant growth impairment, thyroid dysfunction, Leydig cell damage, and the incidence of cataracts.